Novo Nordisk’s Generics Defence in India Offers Blueprint as Amazon Widens US GLP-1 Access
Novo Nordisk’s Ozempic and Wegovy sales rose 40% in India after patent expiry, as generics expand the market.…
Novo Nordisk’s Oral Wegovy Breaks Records, but Generics Threaten to Undercut the Party
Novo Nordisk’s oral Wegovy pill generated 2.26B DKK in Q1, doubling analyst estimates, but generic semaglutide launches in…
Novo Nordisk’s Pill Push Eases the Pain, but the Generics Are Already Circling
Novo Nordisk beats Q1 expectations, raises guidance, and launches oral Ozempic in the US, but adjusted revenue falls…
Generics, Pipeline Wins, and a Pivotal Earnings Report
Novo Nordisk enters a pivotal week with Canada approving first Ozempic generics, oral Ozempic exceeding prescription expectations, and…
Generics, Q1 Results, and a Pipeline Showcase
Novo Nordisk enters a critical period with Q1 earnings, a Canadian Ozempic generic launch, and obesity conference data,…
Generics, Price Wars, and a Steep Valuation Gap
Novo Nordisk faces a turbulent period with a 20% stock drop, Eli Lilly’s US market dominance, and Canada’s…
Novo Nordisk’s Oral Wegovy Pill Surges Past Eli Lilly, but Generics and Price Pressure Loom
Novo Nordisk’s oral Wegovy pill leads Eli Lilly’s Foundayo 2-to-1 in US prescriptions, but faces generic competition in…
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
By Rishika Sadam HYDERABAD, March 19 (Reuters) – India’s market for diabetes and weight-loss drugs is set for…
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
By Rishika Sadam HYDERABAD, March 19 (Reuters) – India’s market for diabetes and weight-loss drugs is set for…
Generic medicine makers prepare to launch affordable options after Novo’s patent for Ozempic, Wegovy expires
Indian firms such as Ajanta Pharma, Dr Reddy’s Laboratories, Lupin, Mankind Pharma and Sun Pharmaceuticals are poised to…